RGPX · As filed with the SEC
Regenerex Pharma balance sheet, by quarter
The statement as Regenerex Pharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
BALANCE SHEETS · USD
| USD | Q2 FY25 Sep 30, 2025 | Q1 FY24 Jun 30, 2025 | Q4 FY24 Mar 31, 2025 | Q3 FY24 Dec 31, 2024 | Q2 FY24 Sep 30, 2024 | Q1 FY24 Jun 30, 2024 | Q4 FY23 Mar 31, 2024 | Q3 FY23 Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Cash and Cash Equivalents | 11,659 | 172,430 | 653,025 | 338 | 294 | — | 372 | 7,856 |
| Prepaid Expenses | 36,770 | 20,250 | 350 | 650 | 1,541 | 2,357 | 2,540 | 1,423 |
| Total Current Assets | 48,429 | 192,680 | 653,375 | 988 | 1,835 | 2,357 | 2,912 | 9,279 |
| Intangible Assets | — | 4,340 | — | — | 208 | 614 | 1,328 | 2,043 |
| Property, Plant and Equipment | — | — | — | — | 5,232 | — | — | — |
| Property, Plant and Equipment | 38,472 | — | — | — | — | — | — | — |
| Property, Plant and Equipment | 3,628 | — | 5,599 | 4,797 | — | 5,667 | 6,097 | 6,527 |
| Operating Lease Right-of-Use Asset | 527,235 | 566,353 | 604,262 | 641,075 | 625,679 | 720,452 | 756,343 | 834,293 |
| Total Assets | 617,764 | 763,373 | 1,263,236 | 646,860 | 632,954 | 729,090 | 766,680 | 852,142 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Accounts Payable | 218,748 | 171,268 | 197,673 | 184,681 | 154,616 | 160,696 | 116,760 | 78,950 |
| Related party advances | — | — | 13,652 | 9,847 | 3,690 | 5,290 | 3,690 | 4,757 |
| Accrued Compensation and Benefits | 808,276 | 862,869 | 842,620 | 802,502 | 705,617 | 608,732 | 511,847 | 414,962 |
| Other Current Liabilities | 154,357 | 25,453 | 88,268 | 141,874 | 126,328 | 106,971 | 97,251 | 83,227 |
| Short-Term Debt | — | — | — | — | — | — | — | 322,246 |
| Current portion of notes payable to shareholder and accrued interest | — | 486,112 | — | — | — | — | — | — |
| Current portion of notes payable to related parties and accrued interest | — | 295,664 | — | — | — | — | — | — |
| Current portion of notes payable to shareholder | 488,797 | — | — | — | — | — | — | — |
| Current portion of notes payable to related parties | 214,584 | — | — | — | — | — | — | — |
| Short-Term Debt | 2,847,737 | 2,843,132 | 2,824,232 | 2,824,232 | 2,824,232 | 2,584,232 | 2,400,000 | 2,400,000 |
| Shareholder | — | — | 469,105 | 611,226 | 621,756 | 604,609 | 475,050 | — |
| Other Affiliates | — | — | 306,103 | 408,262 | 247,976 | 168,726 | 110,500 | — |
| Operating Lease Liability, Current | 191,181 | 167,673 | 181,894 | 177,422 | 166,308 | 174,259 | 128,264 | 152,046 |
| Total Current Liabilities | 4,923,680 | 4,852,171 | 4,923,547 | 5,160,046 | 4,850,523 | 4,413,515 | 3,843,362 | 3,559,688 |
| Notes payable to shareholder, net of current portion | — | — | — | — | — | — | — | 260,788 |
| Long-Term Debt | — | — | — | — | — | — | 119,114 | 184,232 |
| Notes payable to related parties, net of current portion | — | — | — | — | — | — | — | 103,500 |
| Long-Term Debt | — | — | — | — | — | — | 184,232 | — |
| Operating Lease Liability, Non-Current | 392,884 | 458,858 | 495,894 | 540,528 | 539,594 | 628,964 | 681,798 | 723,497 |
| Total Liabilities | 5,316,564 | 5,311,029 | 5,419,441 | 5,700,574 | 5,390,117 | 5,042,479 | 4,828,506 | 4,728,205 |
| Stockholders’ Deficit | ||||||||
| Total Stockholders' Equity | 281,751 | 281,176 | 281,071 | 278,466 | 278,436 | 278,256 | 278,226 | 277,946 |
| Additional Paid-In Capital | 4,639,935 | 3,977,643 | 3,705,615 | 1,400,326 | 1,382,383 | 1,296,765 | 1,275,798 | 1,169,014 |
| Retained Earnings | (9,620,486) | (8,806,475) | (8,142,891) | (6,732,506) | (6,417,982) | (5,888,410) | (5,615,850) | (5,323,023) |
| Total Equity | (4,698,800) | (4,547,656) | (4,156,205) | (5,053,714) | (4,757,163) | (4,313,389) | (4,061,826) | (3,876,063) |
| Total Liabilities and Equity | 617,764 | 763,373 | 1,263,236 | 646,860 | 632,954 | 729,090 | 766,680 | 852,142 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.